ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Excision repair cross complementation group 1 (ERCC1) is a promising biomarker in advanced non-small cell lung cancer (NSCLC). However, current evidence regarding the impact of ERCC1 on toxicity and quality of life (QOL) is limited.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | European Journal of Cancer |
| Vol/bind | 46 |
| Udgave nummer | 9 |
| Sider (fra-til) | 1554-62 |
| Antal sider | 9 |
| ISSN | 0959-8049 |
| DOI | |
| Status | Udgivet - 1 jun. 2010 |
ID: 34096524